systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-371Research ArticleОБЗОРЫИнгибитор ангиотензинпревращающего фермента периндоприл в лечении пациентов с артериальной гипертензиейPerindopril is angiotensin-converting enzyme inhibitor in treatment patients with arterial hypertensionМартыновА. И.MartynovA. I.noemail@neicon.ruУрлаеваИ. В.UrlaevaI. V.noemail@neicon.ruАкатоваЕ. В.AkatovaYe. V.noemail@neicon.ruНиколинО. П.NikolinO. P.noemail@neicon.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииRussian Federation2014231220221137480Copyright © Мартынов А.И., Урлаева И.В., Акатова Е.В., Николин О.П., 20222022Мартынов А.И., Урлаева И.В., Акатова Е.В., Николин О.П.Martynov A.I., Urlaeva I.V., Akatova Y.V., Nikolin O.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/371

Согласно рекомендациям European Society of Hypertension 2013 г. лечение артериальной гипертензии возможно любой из известных групп антигипертензивных препаратов. При этом нередко приходится прибегать к разным комбинациям препаратов. В данной ситуации комбинация препаратов в фиксированной дозе значительно облегчает задачу и увеличивает приверженность пациентов лечению. Результаты многочисленных исследований показали, что периндоприл достоверно снижает общую и сердечно-сосудистую смертность, а также частоту развития инфаркта миокарда, а комбинация его с антагонистом кальция делает препарат еще более эффективным.

According to the 2013 ESH guidelines, it is possible to use any group of known antihypertensive drugs in the treatment of arterial hypertension. But we often have been using different combinations of drugs. In this situation, using drugs combination in fixed dosage increases patients acceptance of therapy and makes treatment easier. According to the results of the numerous studies, perindopril statistically significant reduces total and cardiovascular mortality and the incidence of myocardial infarction. The combination of perindopril and calcium antagonist makes the drug more effective.

артериальная гипертензияпериндоприлПрестариумПрестансASCOTEUROPAPROGRESSSTRONGSYMBIOPERSPECTIVAarterial hypertensionperindoprilPrestariumPrestanceReferencesSever P.S, Dahlof B, Poulter N.R et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 6: 1139-47.Sever P.S, Dahlof B, Poulter N.R et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 6: 1139-47.Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Poulter N.P, Sever P.S. Anglo-Scandinavian Cardiac Outcomes Trial. Caric Print Limited 2005; 108.Poulter N.P, Sever P.S. Anglo-Scandinavian Cardiac Outcomes Trial. Caric Print Limited 2005; 108.Sever P.S, Dahlof B, Poulter N.R et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Sever P.S, Dahlof B, Poulter N.R et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Sever P.S, Dahlof B, Poulter N.R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.Sever P.S, Dahlof B, Poulter N.R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.EURopean trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.EURopean trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.The CAFГ investigators, for the ASCOT investigators. Differential impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213-25.The CAFГ investigators, for the ASCOT investigators. Differential impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213-25.PROGRESS Collaborative Group. Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.PROGRESS Collaborative Group. Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.Rothwell P M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.Rothwell P M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.Poulter N.R, Sever P.S, Dahlof B, Wedel H. ASCOT sub - studes. Anglo- Scandinavian Cardiac Outcomes Trial. Latest perspectives on this landmark trial. 3d ed. Sherborne Gibbs 2011: 35-45.Poulter N.R, Sever P.S, Dahlof B, Wedel H. ASCOT sub - studes. Anglo- Scandinavian Cardiac Outcomes Trial. Latest perspectives on this landmark trial. 3d ed. Sherborne Gibbs 2011: 35-45.Rothwell P.M, Howard S.C, Dolan E et al on behalf of the ASCOTBPLA and MRC Trial Investigators. Effects of b - blockers and calciumchannel blockers on within - individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-80.Rothwell P.M, Howard S.C, Dolan E et al on behalf of the ASCOTBPLA and MRC Trial Investigators. Effects of b - blockers and calciumchannel blockers on within - individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-80.Hatala R, Bachanov K, Sidio R. SYMBIO: results of a longitudinal study of optimized blood pressurelowering therapy with fixed combination perindopril/amlodipine. Abstracts of 20 th European hypertension society meeting. Oslo, 2010.Hatala R, Bachanov K, Sidio R. SYMBIO: results of a longitudinal study of optimized blood pressurelowering therapy with fixed combination perindopril/amlodipine. Abstracts of 20 th European hypertension society meeting. Oslo, 2010.Bangalore S, Kamalakkannan G, Parkar S et al. Fixeddose combinations improve medication compliance: a meta - analysis. Am J Med 2007; 120: 713-9.Bangalore S, Kamalakkannan G, Parkar S et al. Fixeddose combinations improve medication compliance: a meta - analysis. Am J Med 2007; 120: 713-9.Drambyan M, Fljyan N, Makaryan Yu, Ter Margaryan A. The influence of Prestans 10/5 (prestarium + amlodipine) on arterial hypertension and heart rate variability in elderly patients with isolated systolic hypertension. Abstracts of 20th European hypertension society. Oslo, 2010.Drambyan M, Fljyan N, Makaryan Yu, Ter Margaryan A. The influence of Prestans 10/5 (prestarium + amlodipine) on arterial hypertension and heart rate variability in elderly patients with isolated systolic hypertension. Abstracts of 20th European hypertension society. Oslo, 2010.Dolan E.A, Stanton A.V.B, Parker K.H et al on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients - ASCOT substudy. J Hypertens 2009; 27: 876-85.Dolan E.A, Stanton A.V.B, Parker K.H et al on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients - ASCOT substudy. J Hypertens 2009; 27: 876-85.

The authors declare that there are no conflicts of interest present.